drugset / Trial / NCT02904824

Injection Laryngoplasty Using Autologous Fat Enriched With Adipose Derived Regenerative Stem Cells (ADRC)

NCT02904824

Phase 1/2 Completed 16 enrolled Hospital General Universitario Gregorio Marañon
RandomizedParallel-groupOpen-labelTreatment

Summary

This is the first Development Safety Update Report prepared for Phase I-IIA Clinical Trial- FIBHGM-ECNC007-2010 (PHASE I / IIA CLINICAL TRIAL, UNICENTRIC, RANDOMIZED, CONTROLLED, TWO PARALLEL-GROUPS, TO EVALUATE THE SAFETY OF A NEW THERAPY WITH STEM CELLS DERIVED FROM ADIPOSE TISSUE FOR GLOTTAL GAP(GG) IN THE UNILATERAL PARALYSIS OF THE VOCAL CORD(VC) ) in the International Conference on Harmonization (ICH). Patients are randomized to receive one of the following therapeutic strategies: Group A: Autologous Fat processed by centrifugation to fill a paralyzed vocal cord. Group B: Autologous Fat enriched with stem cells from adipose tissue to treat vocal cord paralysis. Active control: Autologous fat tissue processed by centrifugation. Route of administration: Injection into a paralyzed vocal cord. Experimental drug: Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.

Timeline

Start
2012-07
Primary completion
2014-09
Completion
2015-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject adipose-derived regenerative cells Cell therapy Other
Comparator centrifuged autologous fat Unknown Other

Indications

No indication recorded.